Jubilant Pharmova Management
Management criteria checks 1/4
Jubilant Pharmova's CEO is Priyavrat Bhartia, appointed in Jun 2023, has a tenure of less than a year. directly owns 0.88% of the company’s shares, worth ₹959.25M. The average tenure of the management team and the board of directors is 1.3 years and 6.9 years respectively.
Key information
Priyavrat Bhartia
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.9% |
| Management average tenure | 1.3yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt
Nov 27What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?
Nov 17Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Nov 06If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late
Oct 27Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)
Oct 15Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?
Oct 03Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares
Sep 21How Much is Jubilant Life Sciences' (NSE:JUBILANT) CEO Getting Paid?
Sep 20Jubilant Life Sciences Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Sep 08Should You Take Comfort From Insider Transactions At Jubilant Life Sciences Limited (NSE:JUBILANT)?
Sep 03Jubilant Life Sciences Limited's (NSE:JUBILANT) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Aug 24CEO
Priyavrat Bhartia (47 yo)
less than a year
Tenure
Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Group CFO & Whole-Time Director | less than a year | ₹53.43m | no data | |
| Group Chief Digital & Information Officer | no data | ₹16.53m | no data | |
| Company Secretary & Compliance Officer | 1.7yrs | ₹6.86m | no data | |
| Executive VP & Head of Direct Taxation | no data | ₹21.06m | no data | |
| Chief Sustainability Officer | no data | ₹16.73m | no data | |
| MD & Director | less than a year | no data | 0.88% ₹ 959.2m | |
| Joint MD & Director | less than a year | no data | no data | |
| Executive VP of Group Accounts | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP & Head of Legal | 9.4yrs | ₹3.34m | no data | |
| Group Chief Human Resources Officer | 1.3yrs | no data | no data | |
| Advisor | 4.1yrs | ₹67.29m | no data |
1.3yrs
Average Tenure
49yo
Average Age
Experienced Management: JUBLPHARMA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Group CFO & Whole-Time Director | 3yrs | ₹53.43m | no data | |
| MD & Director | 6.9yrs | no data | 0.88% ₹ 959.2m | |
| Joint MD & Director | 6.9yrs | no data | no data | |
| Whole-Time Director | 1.3yrs | no data | no data | |
| Chairman | 45.8yrs | no data | 0.084% ₹ 92.1m | |
| Independent Non-Executive Director | 6.9yrs | ₹1.76m | no data | |
| Independent Non-Executive Director | 5.5yrs | ₹1.38m | 0.0013% ₹ 1.4m | |
| Co-Chairman | 40.4yrs | ₹119.90m | 0.23% ₹ 254.7m | |
| Independent Non-Executive Director | 6.9yrs | ₹1.85m | no data | |
| Additional Independent Non-Executive Director | 1.1yrs | no data | no data |
6.9yrs
Average Tenure
66.5yo
Average Age
Experienced Board: JUBLPHARMA's board of directors are considered experienced (6.9 years average tenure).